Plain-English translation of NCT06282588 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a medication called , when combined with standard hormone therapy and radiation, can help treat high-risk prostate cancer more effectively. Researchers want to understand if this new medication improves survival and quality of life for men whose cancer has spread slightly or has aggressive features. The trial compares this medication to a placebo (inactive pill) to see which approach works best.
High-risk prostate cancer is aggressive and can spread quickly, making it harder to treat with standard therapies alone. This trial aims to find out whether adding this medication to current standard care can prevent cancer from spreading and improve long-term survival.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will have imaging scans and genetic tests on your tumor to determine which group is right for you. You will then either receive the new medication plus standard hormone therapy and radiation (or placebo plus hormone therapy and radiation) for up to 24 months. You will need to attend regular clinic visits for check-ups, blood tests, and imaging scans to monitor how well the treatment is working and watch for side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Belgium